{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:12:00Z","timestamp":1780917120159,"version":"3.54.1"},"reference-count":44,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Teh-Tzer Study Group for Human Medical Research Foundation","award":["B1141022"],"award-info":[{"award-number":["B1141022"]}]},{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"crossref","award":["TSGH-D-115057"],"award-info":[{"award-number":["TSGH-D-115057"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/14756366.2026.2678755","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:32:57Z","timestamp":1780914777000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Lidocaine enhances antitumor effects of sorafenib and GW5074 in colorectal cancer cells"],"prefix":"10.1080","volume":"41","author":[{"given":"Tzu-Chiao","family":"Lin","sequence":"first","affiliation":[{"name":"Division of Colon and Rectal Surgery, Department of Surgery, School of Medicine, College of Medicine, Tri-Service General Hospital, National Defense Medical University","place":["Taipei, Taiwan Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zih-Syuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biochemistry, College of Biomedical Sciences, National Defense Medical University","place":["Taipei City, Taiwan, Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Ming","family":"Huang","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biochemistry, College of Biomedical Sciences, National Defense Medical University","place":["Taipei City, Taiwan, Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biochemistry, College of Biomedical Sciences, National Defense Medical University","place":["Taipei City, Taiwan, Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Ming","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of Colon and Rectal Surgery, Department of Surgery, School of Medicine, College of Medicine, Tri-Service General Hospital, National Defense Medical University","place":["Taipei, Taiwan Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Cheng","family":"Wen","sequence":"additional","affiliation":[{"name":"Division of Colon and Rectal Surgery, Department of Surgery, School of Medicine, College of Medicine, Tri-Service General Hospital, National Defense Medical University","place":["Taipei, Taiwan Republic of China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"1","key":"e_1_3_3_2_1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","article-title":"Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy","volume":"9","author":"Li Q","year":"2024","unstructured":"Li Q, Geng S, Luo H, Wang W, Mo Y-Q, Luo Q, Wang L, Song G-B, Sheng J-P, Xu B. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy. Signal Transduct Target Ther. 2024;9(1):266.","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"e_1_3_3_3_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4240\/wjgs.v15.i4.495","article-title":"Current and emerging therapeutic approaches for colorectal cancer: a comprehensive review","volume":"15","author":"Kumar A","year":"2023","unstructured":"Kumar A, Gautam V, Sandhu A, Rawat K, Sharma A, Saha L. Current and emerging therapeutic approaches for colorectal cancer: a comprehensive review. World J Gastrointest Surg. 2023;15(4):495\u2013519.","journal-title":"World J Gastrointest Surg"},{"issue":"4","key":"e_1_3_3_4_1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","article-title":"Metastatic colorectal cancer: mechanisms and emerging therapeutics","volume":"44","author":"Shin AE","year":"2023","unstructured":"Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharmacol Sci. 2023;44(4):222\u2013236.","journal-title":"Trends Pharmacol Sci"},{"key":"e_1_3_3_5_1","first-page":"597","volume-title":"Sorafenib (BAY 43\u20109006, Nexavar\u00ae), a dual\u2010action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature. Methods Enzymol.","author":"Adnane L","year":"2006","unstructured":"Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43\u20109006, Nexavar\u00ae), a dual\u2010action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597\u2013612."},{"issue":"20","key":"e_1_3_3_6_1","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1158\/1078-0432.CCR-10-0923","article-title":"Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells","volume":"16","author":"Martinelli E","year":"2010","unstructured":"Martinelli E, Troiani T, Morgillo F, Rodolico G, Vitagliano D, Morelli MP, Tuccillo C, Vecchione L, Capasso A, Orditura M, et al. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res. 2010;16(20):4990\u20135001.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"e_1_3_3_7_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/onco.13689","article-title":"Activity of sorafenib plus capecitabine in previously treated metastatic colorectal cancer","volume":"26","author":"George TJ","year":"2021","unstructured":"George TJ, Ivey AM, Ali A, Lee JH, Wang Y, Daily KC, Ramnaraign BH, Tan SA, Terracina KP, Read TE, et al. Activity of sorafenib plus capecitabine in previously treated metastatic colorectal cancer. Oncologist. 2021;26(5):362\u2013e724.","journal-title":"Oncologist"},{"issue":"18","key":"e_1_3_3_8_1","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1158\/1078-0432.CCR-09-0198","article-title":"C-Raf is associated with disease progression and cell proliferation in a subset of melanomas","volume":"15","author":"Jilaveanu LB","year":"2009","unstructured":"Jilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, Camp RL, Rimm DL, Kluger HM. C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin Cancer Res. 2009;15(18):5704\u20135713.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_9_1","doi-asserted-by":"crossref","first-page":"925653","DOI":"10.3389\/fonc.2022.925653","article-title":"The synergistic cytotoxic effects of GW5074 and sorafenib by impacting mitochondrial functions in human colorectal cancer cell lines","volume":"12","author":"Hu JM","year":"2022","unstructured":"Hu JM, Chang YL, Hsieh CC, Huang SM. The synergistic cytotoxic effects of GW5074 and sorafenib by impacting mitochondrial functions in human colorectal cancer cell lines. Front Oncol. 2022;12:925653.","journal-title":"Front Oncol"},{"issue":"17","key":"e_1_3_3_10_1","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1158\/0008-5472.CAN-14-3264","article-title":"Novel cancer therapeutics with allosteric modulation of the mitochondrial C-Raf-DAPK complex by raf inhibitor combination therapy","volume":"75","author":"Tsai YT","year":"2015","unstructured":"Tsai YT, Chuang MJ, Tang SH, Wu ST, Chen YC, Sun GH, Hsiao PW, Huang SM, Lee HJ, Yu CP, et al. Novel cancer therapeutics with allosteric modulation of the mitochondrial C-Raf-DAPK complex by raf inhibitor combination therapy. Cancer Res. 2015;75(17):3568\u20133582.","journal-title":"Cancer Res"},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3389\/fcell.2020.00565","article-title":"Repositioning lidocaine as an anticancer drug: the role beyond anesthesia","volume":"8","author":"Zhou D","year":"2020","unstructured":"Zhou D, Wang L, Cui Q, Iftikhar R, Xia Y, Xu P. Repositioning lidocaine as an anticancer drug: the role beyond anesthesia. Front Cell Dev Biol. 2020;8:565.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"e_1_3_3_12_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/pm\/pnz327","article-title":"Local anesthetics: hunting for the holy grail of onco-anesthesia","volume":"21","author":"Cata JP","year":"2020","unstructured":"Cata JP, Ramirez MF, Perez-Gonzalez O. Local anesthetics: hunting for the holy grail of onco-anesthesia. Pain Med. 2020;21(2):219\u2013220.","journal-title":"Pain Med"},{"issue":"2","key":"e_1_3_3_13_1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3892\/ol.2016.4709","article-title":"Lidocaine inhibits the invasion and migration of TRPV6-expressing cancer cells by TRPV6 downregulation","volume":"12","author":"Jiang Y","year":"2016","unstructured":"Jiang Y, Gou H, Zhu J, Tian S, Yu L. Lidocaine inhibits the invasion and migration of TRPV6-expressing cancer cells by TRPV6 downregulation. Oncol Lett. 2016;12(2):1164\u20131170.","journal-title":"Oncol Lett"},{"issue":"5","key":"e_1_3_3_14_1","article-title":"Lidocaine attenuates TMZ resistance and inhibits cell migration by modulating the MET pathway in glioblastoma cells","volume":"51","author":"Chen MS","year":"2024","unstructured":"Chen MS, Chong ZY, Huang C, Huang HC, Su PH, Chen JC. Lidocaine attenuates TMZ resistance and inhibits cell migration by modulating the MET pathway in glioblastoma cells. Oncol Rep. 2024;51(5):72.","journal-title":"Oncol Rep"},{"key":"e_1_3_3_15_1","doi-asserted-by":"crossref","first-page":"681223","DOI":"10.3389\/fphar.2021.681223","article-title":"Lidocaine promoted ferroptosis by targeting miR-382-5p \/SLC7A11 axis in ovarian and breast cancer","volume":"12","author":"Sun D","year":"2021","unstructured":"Sun D, Li YC, Zhang XY. Lidocaine promoted ferroptosis by targeting miR-382-5p \/SLC7A11 axis in ovarian and breast cancer. Front Pharmacol. 2021;12:681223.","journal-title":"Front Pharmacol"},{"issue":"7","key":"e_1_3_3_16_1","doi-asserted-by":"crossref","first-page":"ix","DOI":"10.4172\/1948-5956.1000e108","article-title":"Drug repurposing for cancer therapy","volume":"4","author":"Telleria CM.","year":"2012","unstructured":"Telleria CM. Drug repurposing for cancer therapy. J Cancer Sci Ther. 2012;4(7):ix\u2013xi.","journal-title":"J Cancer Sci Ther"},{"issue":"1","key":"e_1_3_3_17_1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia Y","year":"2024","unstructured":"Xia Y, Sun M, Huang H, Jin WL. Drug repurposing for cancer therapy. Signal Transduct Target Ther. 2024;9(1):92.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_3_18_1","doi-asserted-by":"crossref","first-page":"107558","DOI":"10.1016\/j.pharmthera.2020.107558","article-title":"Effects of local anesthetics on cancer cells","volume":"212","author":"Liu H","year":"2020","unstructured":"Liu H, Dilger JP, Lin J. Effects of local anesthetics on cancer cells. Pharmacol Ther. 2020;212:107558.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"e_1_3_3_19_1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12885-019-5431-9","article-title":"Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145","volume":"19","author":"Sui H","year":"2019","unstructured":"Sui H, Lou A, Li Z, Yang J. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019;19(1):233.","journal-title":"BMC Cancer"},{"issue":"1","key":"e_1_3_3_20_1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/21691401.2018.1425697","article-title":"Up-regulation of Cav3.1 expression in SH-SY5Y cells induced by lidocaine hydrochloride","volume":"46","author":"Gong Q","year":"2018","unstructured":"Gong Q, Wen X, Li H, He J, Wang Y, Wu H, Wang H, Wang X. Up-regulation of Cav3.1 expression in SH-SY5Y cells induced by lidocaine hydrochloride. Artif Cells Nanomed Biotechnol. 2018;46(sup1):372\u2013379.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"15","key":"e_1_3_3_21_1","article-title":"Chemosensitizer effects of cisplatin- and 5-fluorouracil-treated hepatocellular carcinomas by lidocaine","volume":"26","author":"Chen TW","year":"2025","unstructured":"Chen TW, Fan HL, Liu ST, Huang SM. Chemosensitizer effects of cisplatin- and 5-fluorouracil-treated hepatocellular carcinomas by lidocaine. Int J Mol Sci. 2025;26(15):7137.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"e_1_3_3_22_1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou TC.","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621\u2013681.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"e_1_3_3_23_1","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1038\/s41598-020-59952-x","article-title":"Physical biomarkers of disease progression: on-chip monitoring of changes in mechanobiology of colorectal cancer cells","volume":"10","author":"Armistead FJ","year":"2020","unstructured":"Armistead FJ, Gala De Pablo J, Gad\u00ealha H, Peyman SA, Evans SD. Physical biomarkers of disease progression: on-chip monitoring of changes in mechanobiology of colorectal cancer cells. Sci Rep. 2020;10(1):3254.","journal-title":"Sci Rep"},{"issue":"5","key":"e_1_3_3_24_1","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken NA","year":"2006","unstructured":"Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1(5):2315\u20132319.","journal-title":"Nat Protoc"},{"issue":"2","key":"e_1_3_3_25_1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrm3735","article-title":"Self-consumption: the interplay of autophagy and apoptosis","volume":"15","author":"Mari\u00f1o G","year":"2014","unstructured":"Mari\u00f1o G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 2014;15(2):81\u201394.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"e_1_3_3_26_1","doi-asserted-by":"crossref","first-page":"166742","DOI":"10.1016\/j.bbadis.2023.166742","article-title":"Oxidative stress-induced apoptosis and autophagy: balancing the contrary forces in spermatogenesis","volume":"1869","author":"Sharma P","year":"2023","unstructured":"Sharma P, Kaushal N, Saleth LR, Ghavami S, Dhingra S, Kaur P. Oxidative stress-induced apoptosis and autophagy: balancing the contrary forces in spermatogenesis. Biochim Biophys Acta Mol Basis Dis. 2023;1869(6):166742.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"e_1_3_3_27_1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","article-title":"Ferroptosis: molecular mechanisms and health implications","volume":"31","author":"Tang D","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107\u2013125.","journal-title":"Cell Res"},{"issue":"21","key":"e_1_3_3_28_1","doi-asserted-by":"crossref","first-page":"8119","DOI":"10.3390\/ijms21218119","article-title":"Expression of EMT-related genes in hybrid E\/M colorectal cancer cells determines fibroblast activation and collagen remodeling","volume":"21","author":"Druzhkova I","year":"2020","unstructured":"Druzhkova I, Shirmanova M, Ignatova N, Dudenkova V, Lukina M, Zagaynova E, Safina D, Kostrov S, Didych D, Kuzmich A, et al. Expression of EMT-related genes in hybrid E\/M colorectal cancer cells determines fibroblast activation and collagen remodeling. Int J Mol Sci. 2020;21(21):8119.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"e_1_3_3_29_1","doi-asserted-by":"crossref","first-page":"27663","DOI":"10.1038\/s41598-024-78776-7","article-title":"Colorectal carcinoma progression is not influenced by the pseudokinase PEAK1","volume":"14","author":"Zuidema A","year":"2024","unstructured":"Zuidema A, Atherton P, van der Poel S, Kreft M, Song J-Y, Bierbooms M, Verhoeven S, Papagianni C, Kroese L, Ali RB, et al. Colorectal carcinoma progression is not influenced by the pseudokinase PEAK1. Sci Rep. 2024;14(1):27663.","journal-title":"Sci Rep"},{"issue":"13","key":"e_1_3_3_30_1","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3390\/cancers17132163","article-title":"Exploring experimental models of colorectal cancer: a critical appraisal from 2D cell systems to organoids, humanized mouse avatars, organ-on-chip, CRISPR engineering, and AI-driven platforms-challenges and opportunities for translational precision oncology","volume":"17","author":"Al-Kabani A","year":"2025","unstructured":"Al-Kabani A, Huda B, Haddad J, Yousuf M, Bhurka F, Ajaz F, Patnaik R, Jannati S, Banerjee Y. Exploring experimental models of colorectal cancer: a critical appraisal from 2D cell systems to organoids, humanized mouse avatars, organ-on-chip, CRISPR engineering, and AI-driven platforms-challenges and opportunities for translational precision oncology. Cancers. 2025;17(13):2163.","journal-title":"Cancers"},{"issue":"2","key":"e_1_3_3_31_1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.20517\/cdr.2022.136","article-title":"Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects","volume":"6","author":"Gmeiner WH","year":"2023","unstructured":"Gmeiner WH, Okechukwu CC. Review of 5-FU resistance mechanisms in colorectal cancer: clinical significance of attenuated on-target effects. Cancer Drug Resist. 2023;6(2):257\u2013272.","journal-title":"Cancer Drug Resist"},{"issue":"7899","key":"e_1_3_3_32_1","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","article-title":"Effective drug combinations in breast, colon and pancreatic cancer cells","volume":"603","author":"Jaaks P","year":"2022","unstructured":"Jaaks P, Coker EA, Vis DJ, Edwards O, Carpenter EF, Leto SM, Dwane L, Sassi F, Lightfoot H, Barthorpe S, et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature. 2022;603(7899):166\u2013173.","journal-title":"Nature"},{"issue":"11","key":"e_1_3_3_33_1","doi-asserted-by":"crossref","first-page":"e0188100","DOI":"10.1371\/journal.pone.0188100","article-title":"In-depth phenotypic characterization of multicellular tumor spheroids: effects of 5-fluorouracil","volume":"12","author":"Virgone-Carlotta A","year":"2017","unstructured":"Virgone-Carlotta A, Lemasson M, Mertani HC, Diaz JJ, Monnier S, Dehoux T, Delano\u00eb-Ayari H, Rivi\u00e8re C, Rieu JP. In-depth phenotypic characterization of multicellular tumor spheroids: effects of 5-fluorouracil. PLoS One. 2017;12(11):e0188100.","journal-title":"PLoS One"},{"issue":"6","key":"e_1_3_3_34_1","doi-asserted-by":"crossref","first-page":"115804","DOI":"10.1016\/j.celrep.2025.115804","article-title":"Cell death and cancer: metabolic interconnections","volume":"44","author":"Dalseno D","year":"2025","unstructured":"Dalseno D, Gajic N, Flanagan L, Tait SWG. Cell death and cancer: metabolic interconnections. Cell Rep. 2025;44(6):115804.","journal-title":"Cell Rep"},{"issue":"22","key":"e_1_3_3_35_1","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.3748\/wjg.v22.i22.5193","article-title":"Chitooligosaccharides promote radiosensitivity in colon cancer line SW480","volume":"22","author":"Han FS","year":"2016","unstructured":"Han FS, Yang SJ, Lin MB, Chen YQ, Yang P, Xu JM. Chitooligosaccharides promote radiosensitivity in colon cancer line SW480. World J Gastroenterol. 2016;22(22):5193\u20135200.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"e_1_3_3_36_1","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/030089161309900210","article-title":"Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer","volume":"99","author":"Jeong YK","year":"2013","unstructured":"Jeong YK, Kim MS, Lee JY, Kim EH, Kim W, Ha H, Jeong JH. Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer. Tumori. 2013;99(2):176\u2013182.","journal-title":"Tumori"},{"issue":"22","key":"e_1_3_3_37_1","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1093\/nar\/gkaa1002","article-title":"A unified model for the G1\/S cell cycle transition","volume":"48","author":"Hume S","year":"2020","unstructured":"Hume S, Dianov GL, Ramadan K. A unified model for the G1\/S cell cycle transition. Nucleic Acids Res. 2020;48(22):12483\u201312501.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"e_1_3_3_38_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1747-1028-4-13","article-title":"Regulation of DNA replication by the S-phase DNA damage checkpoint","volume":"4","author":"Willis N","year":"2009","unstructured":"Willis N, Rhind N. Regulation of DNA replication by the S-phase DNA damage checkpoint. Cell Div. 2009;4(1):13.","journal-title":"Cell Div"},{"issue":"10","key":"e_1_3_3_39_1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41419-023-06154-8","article-title":"Autophagy: regulator of cell death","volume":"14","author":"Liu S","year":"2023","unstructured":"Liu S, Yao S, Yang H, Liu S, Wang Y. Autophagy: regulator of cell death. Cell Death Dis. 2023;14(10):648.","journal-title":"Cell Death Dis"},{"issue":"1","key":"e_1_3_3_40_1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang W","year":"2020","unstructured":"Tang W, Chen Z, Zhang W, Cheng Y, Zhang B, Wu F, Wang Q, Wang S, Rong D, Reiter FP, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther. 2020;5(1):87.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_3_41_1","doi-asserted-by":"crossref","first-page":"105732","DOI":"10.1016\/j.phrs.2021.105732","article-title":"New frontiers against sorafenib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers","volume":"170","author":"He Y","year":"2021","unstructured":"He Y, Luo Y, Huang L, Zhang D, Wang X, Ji J, Liang S. New frontiers against sorafenib resistance in renal cell carcinoma: from molecular mechanisms to predictive biomarkers. Pharmacol Res. 2021;170:105732.","journal-title":"Pharmacol Res"},{"issue":"19","key":"e_1_3_3_42_1","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm SM","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099\u20137109.","journal-title":"Cancer Res"},{"issue":"42","key":"e_1_3_3_43_1","doi-asserted-by":"crossref","first-page":"35217","DOI":"10.1074\/jbc.M506551200","article-title":"Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation","volume":"280","author":"Rahmani M","year":"2005","unstructured":"Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005;280(42):35217\u201335227.","journal-title":"J Biol Chem"},{"issue":"8","key":"e_1_3_3_44_1","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.3390\/jcm11082183","article-title":"Phase I targeted combination trial of sorafenib and GW5074 in patients with advanced refractory solid tumors","volume":"11","author":"Kao CC","year":"2022","unstructured":"Kao CC, Ho CL, Yang MH, Tsai YT, Liu SY, Chang PY, Wu YY, Chen JH, Huang TC, Yehn RH, et al. Phase I targeted combination trial of sorafenib and GW5074 in patients with advanced refractory solid tumors. J Clin Med. 2022;11(8):2183.","journal-title":"J Clin Med"},{"issue":"11","key":"e_1_3_3_45_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney J","year":"2015","unstructured":"Guinney J, Dienstmann R, Wang X, de Reyni\u00e8s A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350\u20131356.","journal-title":"Nat Med"}],"container-title":["Journal of Enzyme Inhibition and Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14756366.2026.2678755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:33:04Z","timestamp":1780914784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14756366.2026.2678755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/14756366.2026.2678755"],"URL":"https:\/\/doi.org\/10.1080\/14756366.2026.2678755","relation":{},"ISSN":["1475-6366","1475-6374"],"issn-type":[{"value":"1475-6366","type":"print"},{"value":"1475-6374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ienz20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2678755"}}